Allergan plc, Moleculin Biotech Inc, Estee Lauder Companies Inc, Abercrombie & Fitch Co - PRE-MARKET
Biotech stocks were in play before the bell in New York ..
Company
Allergan
NYSE:AGN
Allergan is a global specialty pharmaceutical company, which develops and commercialises products for eye care, neuromodulator, skin care and other specialty markets. Its products are sold in over 100 countries worldwide and include the successful and popular Botox and Botox cosmetics treatments.
90 stories · page 2 of 5
Allergan to appeal against RESTASIS patents verdict
Allergan enlisted the aid of the Mohawk tribe in an effort to protect its patents
Allergan’s Botox gets US FDA green light to treat forehead lines
The latest approval makes the brand the first and only neurotoxin to be indicated for three facial treatment areas
Allergan shares puff up in pre-market as it announces latest share buy-back and reaffirms dividend commitment
It also reassured investors by saying it will pay down its US$3.75bn (£2.78bn) debt pile next year
Allergan accused of taking advantage of tribal sovereignty in patent dispute with Mylan
Allergan has transferred several patents relating to Restasis to the Native American St. Regis Mohawk Tribe
American Airlines Group Inc, Allergen plc, Centene Corp and Walt Disney Co - PRE-MARKET
We take a look at what's moving the dial in pre-market deals in New York
Allergan shares move lower as second quarter losses almost double year-on-year
For the three months ended June 30, the pharma group reported a second quarter loss of US$2.35, an 88% increase compared to the same period last year
Allergan edges higher on first quarter beat and full-year guidance upgrade
Excluding items, earnings per share came in at US$3.35, 5 cents ahead of the Wall Street consensus
Small Pharma raises £830,000 from angel investors to develop ketamine-based drug as severe depression treatment
The firm, a London-based start-up, said the funds raised will be supplemented by a £140,000 grant from Innovate UK to support the development of a rapid-acting drug
Allergan to push on with final trial for Botox for depression
Results were were close to those achieved from antidepressants on the market
Allergan to put forward new acne drug after good trials
Allergan intends to submit an application to the US Food & Drug Administration (FDA) in the second half of 2017.
Gene editing pioneer Editas agrees US$90m collaboration with Allergan
Editas is one of three companies currently locked in a courtroom battle over the ownership of the gene-editing technique CRISPR
Allergan to buy body contouring company Zeltiq Aesthetics
Pharmaceutical group Allergan has announced the acquisition of Zeltiq Aesthetics for $2.475bn to gain access to its body contouring technology.
US stocks close higher but off record peaks as oil prices fall
US stocks closed higher on Monday but off their intraday highs, as falling oil prices took the shine off a rally
Allergan smiling again after Botox boost
After a disappointing previous three months, the Dublin-based pharma beat expectations this time.
US stocks recover from losses as analysts focus on surprise gasoline supply drop
US stocks recovered from intraday losses to end higher on Wednesday after analysts focused on a fall in gasoline inventories rather than a spike in oil supplies
Allergan to buy LifeCell for $2.9bn cash
Allergan, the maker of wrinkle-filler Botox, said on Tuesday that it has agreed to buy regenerative medicine company LifeCell for $2.9bn in cash
Teva to defend its Actavis UK division amid claims of “unfair” price hike
The UK’s competition watchdog said the business may have broken competition laws after it hiked the price of a drug
Trending: Valeant tries to be valiant
It may seem the phrase manufactured misfortune was invented for Valeant Pharmaceuticals Intl
US stocks end mixed as winners and losers assess Trump
US stocks seesawed through Thursday, with the Dow hitting a record high intraday and close, as banks and pharma stocks lapped up the perceived benefits of President-elect Donald Trump’s victory, while tech stocks sank on worries about his f